The treatment of atherosclerosis by infusions of Na-EDTA started in the USA as early as 1956. It became more and more popular in the US, where many people had to pay for their treatment themselves and highly valued this non-operative, safe and efficient outpatient treatment. It took 50 years until in November 2012, a large scale TACT study financed by the US National Institute of Health was published and confirmed the experience of chelation therapists scientifically: TACT examined 1,708 patients with coronary heart disease after myocardial infarction in a double-blinded, controlled, randomized design. The patients received 40 chelation infusions or placebo, the follow up was 5 years on average. Chelation therapy reduced the primary end points of death, myocardial infarction, stroke, hospitalisation for angina or revascularisation by 18 %, which was statistically significant.
The treatment is given as an intravenous infusion over 3 hours. The basic treatment in atherosclerosis (coronary heart disease, stroke, claudication) consists of 30 infusions, given from once every second week to three times a week usually. After the first 30 infusions, the treatment is given every 2-3 months. In prevention, usually 20 treatments are given.
Pregnant women should not be treated with Na-EDTA, but are usually not in an age group suffering from atherosclerosis. Kidney, heart and liver failure of different stages are contraindications.